This article relies largely or entirely on a single source . Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources. Find sources: "Metaproscaline" – news · newspapers · books · scholar · JSTOR (November 2022) |
| | |
| Clinical data | |
|---|---|
| Other names | 3,4-Dimethoxy-5-propoxyphenethylamine |
| Routes of administration | Oral [1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H21NO3 |
| Molar mass | 239.315 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Metaproscaline, or 3,4-dimethoxy-5-propoxyphenethylamine, is a lesser-known psychedelic drug of the scaline family. It is an analogue of proscaline. Metaproscaline was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved) , the dose and duration are unknown. [1] Metaproscaline produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of metaproscaline.
| | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |